Yahoo · Oct 29, 2026
What Is Behind Liquidia's Lead Over Its Industry?
For questions about this article or underlying research, email [email protected].
LQ
NASDAQ · LQDA
Liquidia Corporation
Healthcare · Biotechnology
$42.20
Up+$5.64 (+13.35%)
Updated Nov 4, 2026, 4:01 PM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.79B
- P/E ratio
- -23.12
- Dividend yield
- 0.00%
- 52-week range
- $22.31 – $93.61
- Volume
- 2.18M
- Avg. volume
- 2.44M
Price performance · LQDA
LQDA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
LQDA closed at $42.20 after 21 trading sessions, up 62.87% for the selected period.
- Last close
- $42.20
- Period change
- +62.87%
- Period low
- $25.91
- Period high
- $45.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $41.69 | $43.37 | $41.52 | $42.20 | 2.18M |
| Nov 2, 2026 | $45.71 | $45.71 | $41.65 | $41.85 | 2.59M |
| Oct 30, 2026 | $44.555 | $46.29 | $44.24 | $45.06 | 2.09M |
| Oct 29, 2026 | $46.23 | $47.20 | $44.41 | $44.99 | 2.64M |
| Oct 28, 2026 | $45.425 | $47.18 | $45.0001 | $45.72 | 2.27M |
| Oct 27, 2026 | $43.88 | $46.36 | $43.695 | $45.44 | 3.18M |
| Oct 26, 2026 | $42.77 | $45.72 | $42.1201 | $43.74 | 4.12M |
| Oct 23, 2026 | $39.86 | $42.83 | $38.69 | $42.65 | 3.81M |
| Oct 22, 2026 | $38.75 | $40.08 | $38.215 | $39.69 | 3.53M |
| Oct 21, 2026 | $36.65 | $39.20 | $36.51 | $38.86 | 3.88M |
| Oct 20, 2026 | $33.90 | $36.93 | $33.65 | $36.35 | 4M |
| Oct 19, 2026 | $34.42 | $36.82 | $33.755 | $34.13 | 3.03M |
| Oct 16, 2026 | $34.78 | $34.90 | $33.33 | $34.35 | 4.55M |
| Oct 15, 2026 | $34.93 | $35.80 | $32.20 | $34.78 | 7.23M |
| Oct 14, 2026 | $35.70 | $38.64 | $33.12 | $33.94 | 21.14M |
| Oct 13, 2026 | $27.04 | $27.40 | $26.13 | $26.81 | 7.65M |
| Oct 12, 2026 | $29.27 | $30.86 | $27.275 | $27.67 | 4.41M |
| Oct 9, 2026 | $27.06 | $28.53 | $26.665 | $27.38 | 3.62M |
| Oct 8, 2026 | $26.34 | $29.35 | $26.34 | $28.02 | 5.26M |
| Oct 7, 2026 | $25.55 | $27.33 | $24.59 | $26.68 | 6.99M |
| Oct 6, 2026 | $27.95 | $28.30 | $25.76 | $25.91 | 5.31M |
Latest LQDA news
The latest Smart Investors Daily articles mentioning LQDA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LQDA research
Overview
Company profile and research snapshot.
Company profile
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.33
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 14, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 14, 2026 | BTIG | Buy | — |
| Oct 14, 2026 | Needham | Buy | — |
| Oct 14, 2026 | LifeSci Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Yahoo · Oct 26, 2026
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 24, 2026
Can Liquidia (LQDA) Still Justify Its Price After Settlement?
Liquidia has seen sharp swings in recent years, and the question now is whether the current share price lines up with what its earnings can reasonably support. With such a volatile backdrop, the issue is not just where the stock has come from, but what the current valuation assumes about the business from here. Over the past 5 years the stock has delivered a very large gain, which puts extra focus on whether the present market value matches what the underlying earnings profile can...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
